Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart
- PMID: 11131640
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart
Abstract
P-glycoprotein (P-gp) and multidrug resistance related protein (MRP) overexpression is often responsible of the development of multidrug resistance in cancer therapy. These proteins are also expressed in normal tissues, where their physiological role is related to the extrusion of endogenous toxins or to secretory function in liver and kidney. The LLC-PK1 cell line is derived from normal pig proximal renal tubule and physiologically expresses low levels of P-gp and MRP. A resistant cell line (LLC-PK1/ADR) has been established in our laboratory by chronic exposure to increasing doses of doxorubicin. Cytofluorimetric analysis of P-gp and MRP expression performed by C219 and MRPm6 immunofluorescence detection showed that these cells overexpress P-gp but not MRP. The uptake of doxorubicin and rhodamine 123 has been quantified in LLC-PK1 and LLC-PK1/ADR cells and compared with data obtained using other tumor cell lines commonly used as reference for studying P-gp or MRP overexpression. P388 sensitive cells and its resistant counterpart P388/ADR cells, which overexpress P-gp and PANC-1 cells, which express high levels of MRP were used. A lower fluorescence intensity was evident with both doxorubicin and rhodamine 123 in LLC-PK1/ADR as well as in P388/ADR cells, that overexpresses P-gp, in comparison with the parental lines. The uptake was increased by a pretreatment with verapamil. Verapamil was completely ineffective on PANC-1 cells, confirming a selective effect of this inhibitor on P-gp. Propidium iodide staining, performed after doxorubicin treatment, confirmed a higher cytotoxicity of the antineoplastic drug in the LLC-PK1 cells compared with the resistant counterpart.
Similar articles
-
Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.Eur J Pharm Sci. 2000 Sep;11(3):207-14. doi: 10.1016/s0928-0987(00)00097-x. Eur J Pharm Sci. 2000. PMID: 11042226
-
Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart.Biochem Pharmacol. 2001 Jan 1;61(1):61-6. doi: 10.1016/s0006-2952(00)00535-9. Biochem Pharmacol. 2001. PMID: 11137710
-
Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport.Histochem J. 1999 Oct;31(10):635-43. doi: 10.1023/a:1003893218761. Histochem J. 1999. PMID: 10576412
-
[Multidrug resistance protein (MRP)].Nihon Rinsho. 1997 May;55(5):1077-82. Nihon Rinsho. 1997. PMID: 9155156 Review. Japanese.
-
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.Cancer Control. 2003 Mar-Apr;10(2):159-65. doi: 10.1177/107327480301000207. Cancer Control. 2003. PMID: 12712010 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous